Rosacea is a chronic inflammatory disease that primarily affects the facial area, with a complex pathogenesis and a variety of treatment options. In recent years, with deeper research into the pathogenesis of rosacea, it has been discovered that the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) signalling pathway may be involved in the development of rosacea, and JAK inhibitors are expected to become a new therapeutic approach for rosacea. This paper reviews the mechanisms, clinical efficacy, and safety of JAK inhibitors in the treatment of rosacea.
Rosacea Research Center, Chinese Society of Dermatology, Rosacea Professional Committee, Chinese Dermatologist Association. Guidelines for the diagnosis and treatment of rosacea in China (2021 edition). Chin J Dermatol. 2021;54(4):279-288. doi:10.35541/cjd.20201078
2.
WeiZYangY. Role of ion channels in the pathogenesis of rosacea. Chin J Dermatol. 2024;57(2):174-177. doi:10.35541/cjd.20230374
3.
ChenCWangPZhangL, et al. Exploring the pathogenesis and mechanism-targeted treatments of rosacea: previous understanding and updates. Biomedicines. 2023;11(8):2153. doi:10.3390/biomedicines11082153
4.
FisherGWTraversJBRohanCA. Rosacea pathogenesis and therapeutics: current treatments and a look at future targets. Front Med. 2023;10:1292722. doi:10.3389/fmed.2023.1292722
5.
WangYXieHLiJ, et al. JAK-STAT signaling pathway and rosacea. Chin J Dermatol. 2023;56(2):169-172. doi:10.35541/cjd.20200592
6.
XinPXuXDengC, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210. doi:10.1016/j.intimp.2020.106210
7.
HuXLiJFuM, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402. doi:10.1038/s41392-021-00791-1
8.
O’SheaJJKontziasAYamaokaK, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111-ii115. doi:10.1136/annrheumdis-2012-202576
9.
BanerjeeSBiehlAGadinaM, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521-546. doi:10.1007/s40265-017-0701-9
10.
PhilipsRLWangYCheonH, et al. The JAK-STAT pathway at 30: much learned, much more to do. Cell. 2022;185(21):3857-3876. doi:10.1016/j.cell.2022.09.023
11.
FragoulisGEMcInnesIBSiebertS. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i43-i54. doi:10.1093/rheumatology/key276
12.
TavolettiGAvalloneGConfortiC, et al. Topical ruxolitinib: a new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023;37(11):2222-2230. doi:10.1111/jdv.19162
13.
LiTLiuYYeL. Advances in research on small molecule Janus kinase inhibitors. Prog Pharm Sci. 2023;47(3):207-216. doi:10.20053/j.issn1001-5094.2023.03.005
14.
WangYWangBHuangY, et al. Multi-transcriptomic analysis and experimental validation implicate a central role of STAT3 in skin barrier dysfunction induced aggravation of rosacea. J Inflamm Res. 2022;15:2141-2156. doi:10.2147/JIR.S356551
15.
BoninoCBAriaNMRicoML, et al. Granulomatous rosacea: a clue to the diagnosis of STAT1 gain of function in a child with immunodeficiency. Clin Exp Dermatol. 2024;49(5):516-518. doi:10.1093/ced/llad442
16.
DengZLiuFChenM, et al. Keratinocyte-immune cell crosstalk in a STAT1-mediated pathway: novel insights into rosacea pathogenesis. Front Immunol. 2021;12:674871. doi:10.3389/fimmu.2021.674871
17.
MengXZhongYKuangX, et al. Targeting the STAT3/IL-36G signaling pathway can be a promising approach to treat rosacea. J Adv Res. 2024. Published online June 22, 2024.doi:10.1016/j.jare.2024.06.013
18.
XueCXieJZhaoD, et al. The JAK/STAT3 signalling pathway regulated angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model. Cell Prolif. 2017;50(1):e12307. doi:10.1111/cpr.12307
19.
SunRFanHLiuJ, et al. The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathway. Arch Dermatol Res. 2024;316(8):566. doi:10.1007/s00403-024-03314-4
20.
KumariASrivastavaAJagdaleP, et al. Lambda-cyhalothrin enhances inflammation in nigrostriatal region in rats: regulatory role of NF-κβ and JAK-STAT signaling. Neurotoxicology. 2023;96:101-117. doi:10.1016/j.neuro.2023.04.003
21.
AwadSMTawfikYMEl-MokhtarMA, et al. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther. 2021;34(1):e14563. doi:10.1111/dth.14563
22.
LuuKGreenhillCJMajorosA, et al. STAT1 plays a role in TLR signal transduction and inflammatory responses. Immunol Cell Biol. 2014;92(9):761-769. doi:10.1038/icb.2014.51
23.
LiuYDYuLYingL, et al. Toll-like receptor 2 regulates metabolic reprogramming in gastric cancer via superoxide dismutase 2. Int J Cancer. 2019;144(12):3056-3069. doi:10.1002/ijc.32060
24.
ZhouJLiTChenH, et al. ADAMTS10 inhibits aggressiveness via JAK/STAT/c-MYC pathway and reprograms macrophage to create an anti-malignant microenvironment in gastric cancer. Gastric Cancer. 2022;25(6):1002-1016. doi:10.1007/s10120-022-01319-4
25.
WangYYuXSongH, et al. The STAT-ROS cycle extends IFN‑induced cancer cell apoptosis. Int J Oncol. 2018;52(1): 305-313. doi:10.3892/ijo.2017.4196
26.
OetjenLKMackMRFengJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-228.e13. doi:10.1016/j.cell.2017.08.006
27.
EricksonSHeulAVKimBS. New and emerging treatments for inflammatory itch. Ann Allergy Asthma Immunol. 2021;126(1):13-20. doi:10.1016/j.anai.2020.05.028
28.
DingXYangYHuangY. Application prospect of JAK inhibitors in pruritic inflammatory dermatosis. Herald Med. 2022;41(11):1642-1646. doi:10.3870/j.issn.1004-0781.2022.11.012
29.
SunYHManXYXuanXY, et al. Tofacitinib for the treatment of erythematotelangiectatic and papulopustular rosacea: a retrospective case series. Dermatol Ther. 2022;35:e15848. doi:10.1111/dth.15848
30.
LiTWangHWangC, et al. Tofacitinib for the treatment of steroid-induced rosacea. Clin Cosmet Investig Dermatol. 2022;15:2519-2521. doi:10.2147/CCID.S392280
31.
CaoYAiLHanCHanJ. Evaluation of the efficacy of tofacitinib in the treatment of refractory rosacea in 3 cases. Dermatol Venereol. 2023;45(1):66-69. doi:10.3969/j.issn.1002-1310.2023.01.016
32.
XuBXuZYeS, et al. JAK1 inhibitor Abrocitinib for the treatment of steroid-induced rosacea: case series. Front Med. 2023;10:1239869. doi:10.3389/fmed.2023.1239869
33.
RenMYangXTengY, et al. Successful treatment of granulomatous rosacea by JAK inhibitor Abrocitinib: a case report. Clin Cosmet Investig Dermatol. 2023;16:3369-3374. doi:10.2147/CCID.S440138
34.
ZhangTLiuXZhangL, et al. Treatment of rosacea with Upadacitinib and Abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea. Front Immunol. 2024;15:1416004. doi:10.3389/fimmu.2024.1416004
35.
Shreberk-HassidimRRamotYZlotogorskiA. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76(4):745-753.e19. doi:10.1016/j.jaad.2016.12.004
36.
ShalabiMGarciaBColemanK, et al. Janus kinase and tyrosine kinase inhibitors in dermatology: a review of their utilization, safety profile and future applications. Skin Therapy Lett. 2022, 27(1):4-9.
37.
ElmariahSBSmithJSMerolaJF. JAK in the [Black] box: a dermatology perspective on systemic JAK inhibitor safety. Am J Clin Dermatol. 2022;23(4): 427-431. doi:10.1007/s40257-022-00701-3
38.
NeumannKTerheydenPThaçiD. [Granulomatous rosacea-like dermatitis under therapy with tofacitinib]. Hautarzt. 2021;72(11):1000-1002. doi:10.1007/s00105-021-04793-6
39.
DaiXZhangCYinZ. Therapy outcomes of IL-17 and JAK inhibitors in rosacea: a systematic review. J Biomed Res. Published online August 25, 2024. doi:10.7555/JBR.38.20240107
